 Duration of novel therapy: Novel therapies will be administered for 6 months before assessing efficacy, i.e., 50 reduction in proteinuria. Although the novel therapies target renal fibrosis, it is anticipated that this period of treatment will be sufficient to document a beneficial effect on proteinuria. 